# Hidradenitis Suppurativa FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/hidradenitis-suppurativa

> 22 upcoming FDA catalysts in hidradenitis Suppurativa: lutikizumab (ABBV) on December 2026 (primary completion); lutikizumab (ABBV) on Dec 2026 to Mar 2027 (topline data readout); Litfulo (ritlecitinib tosylate, PFE) on Dec 2026 to Mar 2027 (topline data readout); Litfulo (ritlecitinib tosylate, PFE) on December 2026 (primary completion); and 18 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| August 14, 2025 | [Sonelokimab primary completion](https://sec-api.dev/pdufa/sonelokimab) | MLTX | Hidradenitis Suppurativa | completed | "NCT06411379 (Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-14 (ACTUAL); Lead Sponsor MoonLake Immunotherapeutics AG." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06411379)) |
| September 2, 2025 | [Sonelokimab primary completion](https://sec-api.dev/pdufa/sonelokimab) | MLTX | Hidradenitis Suppurativa | completed | "NCT06411899 (A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-02 (ACTUAL); Lead Sponsor MoonLake Immunotherapeutics AG." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06411899)) |
| September 30, 2025 | [Eltrekibart primary completion](https://sec-api.dev/pdufa/eltrekibart) | LLY | Hidradenitis Suppurativa | completed | "NCT06046729 (A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-30 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06046729)) |
| October 9, 2025 | [Sar444656 (kt-474) primary completion](https://sec-api.dev/pdufa/sar444656-kt-474) | SNY | Hidradenitis Suppurativa | withdrawn | "NCT06028230 (A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-10-09 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06028230)) |
| February 12, 2026 | [BRINSUPRI® (brensocatib) primary completion](https://sec-api.dev/pdufa/brensocatib) | INSM | Hidradenitis Suppurativa | withdrawn | "NCT06685835 (A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-02-12 (ACTUAL); Lead Sponsor Insmed Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06685835)) |
| February 23, 2026 | [Avtx-009 regimen 1 primary completion](https://sec-api.dev/pdufa/avtx-009-regimen-1) | AVTX | Hidradenitis Suppurativa | completed | "NCT06603077 (A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-23 (ACTUAL); Lead Sponsor Avalo Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06603077)) |
| April 2, 2026 | [Tulisokibart primary completion](https://sec-api.dev/pdufa/tulisokibart) | MRK | Hidradenitis Suppurativa | completed | "NCT06956235 (Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-04-02 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06956235)) |
| May 5, 2026 | [Abdakibart topline data readout](https://sec-api.dev/pdufa/abdakibart) | AVTX | hidradenitis suppurativa | completed, positive | "•On May 5, 2026, Avalo reported positive topline Phase 2 LOTUS results for abdakibart in adults with moderate to severe HS." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534120/000153412026000032/ex-9911q2026earningsrelease.htm)) |
| September 28, 2026 | [Sonelokimab primary completion](https://sec-api.dev/pdufa/sonelokimab) | MLTX | Hidradenitis Suppurativa | completed | "NCT06768671 (An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-28 (ACTUAL); Lead Sponsor MoonLake Immunotherapeutics AG." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06768671)) |
| Sep to Dec 2026 | [Sonelokimab topline data readout](https://sec-api.dev/pdufa/sonelokimab) | MLTX | Hidradenitis Suppurativa | scheduled | "NCT06768671 (An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-28 (ACTUAL); Lead Sponsor MoonLake Immunotherapeutics AG." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06768671)) |
| October 1, 2026 | [Ruxolitinib cream primary completion](https://sec-api.dev/pdufa/ruxolitinib-cream) | INCY | Hidradenitis Suppurativa | completed | "NCT06958211 (Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-01 (ACTUAL); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06958211)) |
| Oct 2026 to Jan 2027 | [Ruxolitinib cream topline data readout](https://sec-api.dev/pdufa/ruxolitinib-cream) | INCY | Hidradenitis Suppurativa | scheduled | "NCT06958211 (Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-01 (ACTUAL); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06958211)) |
| October 29, 2026 | [Ruxolitinib cream primary completion](https://sec-api.dev/pdufa/ruxolitinib-cream) | INCY | Hidradenitis Suppurativa | completed | "NCT06959225 (Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-29 (ACTUAL); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06959225)) |
| Oct 2026 to Jan 2027 | [Ruxolitinib cream topline data readout](https://sec-api.dev/pdufa/ruxolitinib-cream) | INCY | Hidradenitis Suppurativa | scheduled | "NCT06959225 (Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-29 (ACTUAL); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06959225)) |
| December 2026 | [Lutikizumab primary completion](https://sec-api.dev/pdufa/lutikizumab) | ABBV | Hidradenitis Suppurativa | scheduled | "NCT06468228 (A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06468228)) |
| Dec 2026 to Mar 2027 | [Lutikizumab topline data readout](https://sec-api.dev/pdufa/lutikizumab) | ABBV | Hidradenitis Suppurativa | scheduled | "NCT06468228 (A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06468228)) |
| Dec 2026 to Mar 2027 | [Litfulo (ritlecitinib tosylate) topline data readout](https://sec-api.dev/pdufa/ritlecitinib) | PFE | Hidradenitis Suppurativa | scheduled | "NCT07228390 (A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-08 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07228390)) |
| December 2026 | [Litfulo (ritlecitinib tosylate) primary completion](https://sec-api.dev/pdufa/ritlecitinib) | PFE | Hidradenitis Suppurativa | scheduled | "NCT07228390 (A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-08 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07228390)) |
| Feb to May 2027 | [Brivekimig topline data readout](https://sec-api.dev/pdufa/brivekimig) | SNY | Hidradenitis Suppurativa | scheduled | "NCT07170917 (Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02-09 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07170917)) |
| Feb to May 2027 | [Zasocitinib (dose a) topline data readout](https://sec-api.dev/pdufa/zasocitinib-dose-a) | TAK | Hidradenitis Suppurativa | scheduled | "NCT07244263 (A Study of Zasocitinib in Adults With Hidradenitis Suppurativa): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-05 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07244263)) |
| February 2027 | [Zasocitinib (dose a) primary completion](https://sec-api.dev/pdufa/zasocitinib-dose-a) | TAK | Hidradenitis Suppurativa | scheduled | "NCT07244263 (A Study of Zasocitinib in Adults With Hidradenitis Suppurativa): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-05 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07244263)) |
| February 2027 | [Brivekimig primary completion](https://sec-api.dev/pdufa/brivekimig) | SNY | Hidradenitis Suppurativa | scheduled | "NCT07170917 (Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02-09 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07170917)) |
| May to Aug 2027 | [Rhapsido® (remibrutinib) topline data readout](https://sec-api.dev/pdufa/remibrutinib) | NVS | Hidradenitis Suppurativa | scheduled | "NCT06799000 (A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-17 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06799000)) |
| May 2027 | [Rhapsido® (remibrutinib) primary completion](https://sec-api.dev/pdufa/remibrutinib) | NVS | Hidradenitis Suppurativa | scheduled | "NCT06799000 (A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-17 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06799000)) |
| Jun to Sep 2027 | [Rhapsido® (remibrutinib) topline data readout](https://sec-api.dev/pdufa/remibrutinib) | NVS | Hidradenitis Suppurativa | scheduled | "NCT06840392 (A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-03 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06840392)) |
| June 2027 | [Rhapsido® (remibrutinib) primary completion](https://sec-api.dev/pdufa/remibrutinib) | NVS | Hidradenitis Suppurativa | scheduled | "NCT06840392 (A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-03 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06840392)) |
| Sep to Dec 2027 | [SAR445399 topline data readout](https://sec-api.dev/pdufa/sar445399) | SNY | Hidradenitis Suppurativa | scheduled | "NCT07225569 (A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09-22 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07225569)) |
| September 2027 | [SAR445399 primary completion](https://sec-api.dev/pdufa/sar445399) | SNY | Hidradenitis Suppurativa | scheduled | "NCT07225569 (A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09-22 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07225569)) |
| December 2027 | [Lutikizumab primary completion](https://sec-api.dev/pdufa/lutikizumab) | ABBV | Hidradenitis Suppurativa | scheduled | "NCT05139602 (A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05139602)) |
| Dec 2027 to Mar 2028 | [Lutikizumab topline data readout](https://sec-api.dev/pdufa/lutikizumab) | ABBV | Hidradenitis Suppurativa | scheduled | "NCT05139602 (A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05139602)) |
| Jun to Sep 2028 | [Sonelokimab topline data readout](https://sec-api.dev/pdufa/sonelokimab) | MLTX | Hidradenitis Suppurativa | scheduled | "NCT07007637 (A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-06-13 (ESTIMATED); Lead Sponsor MoonLake Immunotherapeutics AG." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07007637)) |
| June 2028 | [Sonelokimab primary completion](https://sec-api.dev/pdufa/sonelokimab) | MLTX | Hidradenitis Suppurativa | scheduled | "NCT07007637 (A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-06-13 (ESTIMATED); Lead Sponsor MoonLake Immunotherapeutics AG." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07007637)) |
| August 2028 | [RINVOQ® (upadacitinib) primary completion](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Hidradenitis Suppurativa | scheduled | "NCT05889182 (A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05889182)) |
| Aug to Nov 2028 | [RINVOQ® (upadacitinib) topline data readout](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Hidradenitis Suppurativa | scheduled | "NCT05889182 (A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05889182)) |
| Nov 2028 to Feb 2029 | [Olatorepatide topline data readout](https://sec-api.dev/pdufa/olatorepatide) | REGN | Hidradenitis Suppurativa | scheduled | "NCT07830329 (Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-11-24 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07830329)) |
| November 2028 | [Olatorepatide primary completion](https://sec-api.dev/pdufa/olatorepatide) | REGN | Hidradenitis Suppurativa | scheduled | "NCT07830329 (Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-11-24 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07830329)) |

## Drugs

- [Sonelokimab](https://sec-api.dev/pdufa/sonelokimab) (MLTX)
- [Eltrekibart](https://sec-api.dev/pdufa/eltrekibart) (LLY)
- [Sar444656 (kt-474)](https://sec-api.dev/pdufa/sar444656-kt-474) (SNY)
- [BRINSUPRI® (brensocatib)](https://sec-api.dev/pdufa/brensocatib) (INSM)
- [Avtx-009 regimen 1](https://sec-api.dev/pdufa/avtx-009-regimen-1) (AVTX)
- [Tulisokibart](https://sec-api.dev/pdufa/tulisokibart) (MRK)
- [Abdakibart](https://sec-api.dev/pdufa/abdakibart) (AVTX)
- [Ruxolitinib cream](https://sec-api.dev/pdufa/ruxolitinib-cream) (INCY)
- [Lutikizumab](https://sec-api.dev/pdufa/lutikizumab) (ABBV)
- [Litfulo (ritlecitinib tosylate)](https://sec-api.dev/pdufa/ritlecitinib) (PFE)
- [Brivekimig](https://sec-api.dev/pdufa/brivekimig) (SNY)
- [Zasocitinib (dose a)](https://sec-api.dev/pdufa/zasocitinib-dose-a) (TAK)
- [Rhapsido® (remibrutinib)](https://sec-api.dev/pdufa/remibrutinib) (NVS)
- [SAR445399](https://sec-api.dev/pdufa/sar445399) (SNY)
- [RINVOQ® (upadacitinib)](https://sec-api.dev/pdufa/upadacitinib) (ABBV)
- [Olatorepatide](https://sec-api.dev/pdufa/olatorepatide) (REGN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/hidradenitis-suppurativa.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Hidradenitis Suppurativa FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/hidradenitis-suppurativa

```bibtex
@misc{secapidev_indications_hidradenitis_suppurativa_20261116,
  title        = {Hidradenitis Suppurativa FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/hidradenitis-suppurativa}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_hidradenitis_suppurativa_20261116","title":"Hidradenitis Suppurativa FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/hidradenitis-suppurativa","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
